Clinical Trial

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2026-01-26.
Status change: Active, Not Recruiting → Completed 2026-01-26
Trial Details
NCT Number NCT06881264
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Enrollment 401 participants
Start Date 2024-04-30
Primary Completion 2025-09-19 (estimated)
Study Completion 2025-09-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-27